---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-064419"
form_type: "8-K"
ticker: "TEM"
cik: "0001717115"
company_name: "Tempus AI, Inc."
filed_at: "2025-05-06T23:59:59+00:00"
generated_at: "2026-05-22T12:55:19.359374+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Tempus Q1 revenue up 75.4% to $255.7M; raises FY2025 revenue guidance to $1.25B

## Summary
- Revenue $255.7M (+75.4% YoY); gross profit $155.2M (+99.8% YoY) with margin improvement in Genomics and Data & Services.
- Net loss $68.0M (incl. $28.2M stock comp & $31.8M fair value losses); adjusted EBITDA -$16.2M vs -$43.9M YoY.
- Collaborations with AstraZeneca and Pathos; $200M in data licensing/model development fees over 3 years.
- Full year 2025 revenue guidance raised to ~$1.25B (~80% growth); expects positive adjusted EBITDA of $5M.
- Genomics revenue $193.8M (+88.9% YoY); Data & Services revenue $61.9M (+43.2% YoY; Insights up 58%).

## SEC filing metadata
- accession: 0000950170-25-064419
- form_type: 8-K
- ticker: TEM
- cik: 0001717115
- company_name: Tempus AI, Inc.
- filed_at: 2025-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1717115/000095017025064419/0000950170-25-064419-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1717115/000095017025064419/tem-20250506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-064419
- JSON: https://secwatch.observer/filing/0000950170-25-064419.json
- Plain text: https://secwatch.observer/filing/0000950170-25-064419.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.